Approaching clinical proteomics: current state and future fields of application in fluid proteomics.
The field of clinical proteomics offers opportunities to identify new disease biomarkers in body fluids, cells and tissues. These biomarkers can be used in clinical applications for diagnosis, stratification of patients for specific treatment, or therapy monitoring. New protein array formats and improved spectrometry technologies have brought these analyses to a level with potential for use in clinical diagnostics. The nature of the human body fluid proteome with its large dynamic range of protein concentrations presents problems with quantitation. The extreme complexity of the proteome in body fluids presents enormous challenges and requires the establishment of standard operating procedures for handling of specimens, increasing sensitivity for detection and bioinformatical tools for distribution of proteomic data into the public domain. From studies of in vitro diagnostics, especially in clinical chemistry, it is evident that most errors occur in the preanalytical phase and during implementation of the diagnostic strategy. This is also true for clinical proteomics, and especially for fluid proteomics because of the multiple pretreatment processes. These processes include depletion of high-abundance proteins from plasma or enrichment processes for urine where biological variation or differences in proteolytic activities in the sample along with preanalytical variables such as inter- and intra-assay variability will likely influence the results of proteomics studies. However, before proteomic analysis can be introduced at a broader level into the clinical setting, standardization of the preanalytical phase including patient preparation, sample collection, sample preparation, sample storage, measurement and data analysis needs to be improved. In this review, we discuss the recent technological advances and applications that fulfil the criteria for clinical proteomics, with the focus on fluid proteomics. These advances relate to preanalytical factors, analytical standardization and quality-control measures required for effective implementation into routine laboratory testing in order to generate clinically useful information. With new disease biomarker candidates, it will be crucial to design and perform clinical studies that can identify novel diagnostic strategies based on these techniques, and to validate their impact on clinical decision-making.
Apweiler
Rolf
R
European Bioinformatics Institute, Welcome Trust Genome Campus, Hinxton, UK.
Aslanidis
Charalampos
C
Deufel
Thomas
T
Gerstner
Andreas
A
Hansen
Jens
J
Hochstrasser
Dennis
D
Kellner
Roland
R
Kubicek
Markus
M
Lottspeich
Friedrich
F
Maser
Edmund
E
Mewes
Hans-Werner
HW
Meyer
Helmut E
HE
Müllner
Stefan
S
Mutter
Wolfgang
W
Neumaier
Michael
M
Nollau
Peter
P
Nothwang
Hans G
HG
Ponten
Fredrik
F
Radbruch
Andreas
A
Reinert
Knut
K
Rothe
Gregor
G
Stockinger
Hannes
H
Tarnok
Attila
A
Taussig
Mike J
MJ
Thiel
Andreas
A
Thiery
Joachim
J
Ueffing
Marius
M
Valet
Günther
G
Vandekerckhove
Joel
J
Verhuven
Wiltrud
W
Wagener
Christoph
C
Wagner
Oswald
O
Schmitz
Gerd
G
D015415:Biomarkers / Q000032:analysis; D001826:Body Fluids / Q000737:chemistry*; D015510:Clinical Medicine / Q000379:methods* / Q000592:standards / Q000639:trends; D011506:Proteins / Q000032:analysis*; D040901:Proteomics / Q000379:methods* / Q000592:standards / Q000639:trends; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
D015415:Biomarkers; D011506:Proteins